No Data
Zhejiang Starry Pharmaceutical (603520.SH): 95.89538 million restricted shares will be unlocked on December 12.
Gelonghui reported on December 8 that zhejiang starry pharmaceutical (603520.SH) issued an announcement regarding the listing and circulation of restricted shares to specific objects, with a total of 95.89538 million stocks being listed. The listing date for these stocks is December 12, 2024.
Zhejiang Starry Pharmaceutical (603520.SH) passed the on-site inspection by the USA FDA.
zhejiang starry pharmaceutical (603520.SH) announced that the company will be holding...
Stari: Stari\'s report for the third quarter of 2024
Stelli\'s report for the third quarter of 2024
Zhejiang Starry Pharmaceutical (603520.SH) released its performance for the first three quarters, with a net income of 8.98 million yuan, a year-on-year decrease of 77.17%.
Zhejiang Starry Pharmaceutical (603520.SH) disclosed its third quarter report for 2024, achieving revenue of 18....
Zhejiang Starry Pharmaceutical (603520.SH): The net income in the first three quarters was 8.9758 million yuan, a year-on-year decrease of 77.17%.
Gelonghui October 30th| Zhejiang Starry Pharmaceutical (603520.SH) announced the third quarter report for 2024, with a company's revenue in the first three quarters of 1.805 billion yuan, a year-on-year increase of 10.65%; the net income attributable to the shareholders of the listed companies was 8.9758 million yuan, a year-on-year decrease of 77.17%; and the basic earnings per share was 0.02 yuan.
Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
